Details

Project TitleEarly Diagnosis for Human Hepatocellular Carcinoma (16087)
Track Code16087
Websitewww.louisville.flintbox.com
Short DescriptionNone
Abstract

Early Diagnosis for Human Hepatocellular Carcinoma (16087)

     

Features and Benefits Summary

  • May provide for detection of presence and aggressiveness of hepatocellular carcinoma

  • May allow for more informed treatment decisions.

 *This Technology is available for licensing, further development, or industrial partnering*

    

Market Opportunities

Hepatocellular carcinoma (HCC) is a highly aggressive solid tumor that develops in the context of chronic liver disease and cirrhosis. HCC is the cause of 70-90% of primary liver cancers, resulting in the second leading cause of cancer deaths among men and the sixth leading cause of cancer deaths amongst women worldwide. Current technology can only detect the presence of HCC and related diseases while this technology may predict the aggressiveness of the cancer as well as its presence. 

       

Technology   

Researchers at the University of Louisville have discovered a biomarker that has been shown to possibly play an important role in non-alcoholic steatohepatitis (NASH), which is closely related to hepatocellular carcinoma. Recently, the researchers have found the biomarker overexpressed in the HCC tissue and serum in patients. The high levels of the biomarker was positively related to cancer stem cells specific surface markers such as CD133 and EpCAMP. There is a high demand for this technology because it may not only can detect presence of a HCC, but it may provide oncologists information as to what type of treatment may be needed, leading to a better prognosis for patients.

     

Technology Status

  • IP Status: Provisional Patent Application
  • Fields of Use Available: All

    

Researchers:

  • Dr. Robert Martin

  • Dr. Yan Li

 
TagsNone
 
Posted DateMar 2, 2017 10:28 AM

Files

File Name Description
Marketing Abstract 16087 PDF Marketing Abstract 16087 Download